Universe of Existence, Universe of Perception: teamLab Biovortex Kyoto Opening on October 7, 2025. Fully Unveiled
2.10.2025 09:00:00 EEST | Business Wire | Press release
teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025.
This museum, located within walking distance of Kyoto Station, will be teamLab's largest exhibition in Japan, spanning over 10,000 square meters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001418827/en/
teamLab, Megaliths © teamLab
The museum will feature more than 50 artworks, including Massless Amorphous Sculpture, an artwork that has never been exhibited in Japan, based on Environmental Phenomena, a concept that the environment which produces the various phenomena causes the artworks to exist. Other artworks include the newly unveiled Megaliths, Transient Abstract Life and Return, as well as Athletics Forest, a complex, multi-dimensional creative athletic space, and Future Park, a collaborative space for co-creation, which are both part of teamLab’s educational projects.
Tickets are now available on the official website.
https://www.teamlab.art/e/kyoto/
This project, a collaboration with several companies based in Kyoto and Osaka, involves establishing and operating a facility on city-owned land in the southeastern area of Kyoto Station. The complex aims to be a "creative hub for generating and disseminating new value," with plans including a complex cultural facility featuring teamLab's art museum and an art center, among other attractions.
Through this project, teamLab aims to support Kyoto City's vision for urban development in the Kyoto Station Southeast Area, centered around culture, art, and youth.
teamLab Biovortex Kyoto
Opening October 7th, 2025
21-5 Higashikujo Higashi-Iwamotocho, Minami-ku, Kyoto
Ticket Prices
Entrance Pass (Admission time is specified)
* This is a timed-entry ticket.
* Adult admission fees are based on a variable pricing system, so the price varies depending on the date and time. Please check the official website for details.
Adults (18 and above): JPY 3,400 ~
13–17 years: JPY 2,800
4–12 years: JPY 1,800
3 years and under: Free
Visitors with disabilities: 50% off the adult price
Flexible Pass (Admission time is not specified):
* This is a date-specific ticket. You can enter anytime during our open hours on your selected date.
Flexible Pass: JPY 12,000
Ticket
https://www.teamlab.art/e/kyoto/
Sponsorship
CHIEF, Klook, THIRDWAVE
For Media
Press Kit: https://www.dropbox.com/scl/fo/93lvrprtgnfgv7fetmdkh/AEWRAiT_cvPAO96U6t39MTo?rlkey=lthlq82v8w9ar71j3vyh3j6oq&st=b447so0p&dl=0
Official Website: https://www.teamlab.art/e/kyoto/
View source version on businesswire.com: https://www.businesswire.com/news/home/20251001418827/en/
Contacts
teamLab
E-mail: lab-pr-info@team-lab.com
Media Inquiries: https://forms.gle/LnSSKQtgXpSfrB917 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fforms.gle%2FLn
SSKQtgXpSfrB917&esheet=54330628&newsitemid=20251001418827&lan=en-US&anchor=https
%3A%2F%2Fforms.gle%2FLnSSKQtgXpSfrB917&index=11&md5=1e4c56e87c89146343613af2b721
33cc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom